ImageneBio Overview
Valuation check: IMA's ROE is -44.73%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-44.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
ImageneBio (IMA) currently reports a ROE of -44.73%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore ImageneBio's ROE history and peer comparisons.
ImageneBio's ROE of -44.73% is lower than the Healthcare sector average of 29.33%. That is roughly 252.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but ImageneBio's current -44.73% should be judged against Healthcare norms (sector average: 29.33%) and against IMA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -44.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for ImageneBio, and consider following IMA for alerts when major investors trade the stock.
ImageneBio is classified in the Healthcare sector. On ROE, it currently shows -44.73% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMA with unrelated industries.
